Artikler med mandater om offentlig tilgang - Rita NandaLes mer
Ikke tilgjengelige noe sted: 6
Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): a randomized clinical trial
SM Tolaney, N Tayob, C Dang, DA Yardley, SJ Isakoff, V Valero, ...
Journal of Clinical Oncology 39 (21), 2375-2385, 2021
Mandater: Susan G. Komen
TBCRC-010: phase I/II study of dasatinib in combination with zoledronic acid for the treatment of breast cancer bone metastasis
Z Mitri, R Nanda, K Blackwell, CM Costelloe, I Hood, C Wei, AM Brewster, ...
Clinical Cancer Research 22 (23), 5706-5712, 2016
Mandater: Susan G. Komen
Assessment of provider-perceived barriers to clinical use of pharmacogenomics during participation in an institutional implementation study
BA Borden, P Galecki, R Wellmann, K Danahey, SM Lee, L Patrick-Miller, ...
Pharmacogenetics and Genomics 29 (2), 31-38, 2019
Mandater: US National Institutes of Health
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH)(TBCRC033: ATEMPT Trial)
KJ Ruddy, Y Zheng, N Tayob, J Hu, CT Dang, DA Yardley, SJ Isakoff, ...
Breast Cancer Research and Treatment 189 (1), 103-110, 2021
Mandater: Susan G. Komen
Racial/ethnic disparities in telemedicine utilization and satisfaction among breast cancer patients during the COVID-19 pandemic: a mixed-methods analysis
JQ Freeman, A Khwaja, F Zhao, R Nanda, OI Olopade, D Huo
Telemedicine and e-Health 30 (3), 651-663, 2024
Mandater: US National Institutes of Health, Susan G. Komen
Retrospective evaluation of adjuvant capecitabine dosing patterns in triple negative breast cancer
K Lin, E Michaels, E Polley, PH O’Donnell, FM Howard, O Hahn, ...
Journal of Oncology Pharmacy Practice, 10781552241289581, 2023
Mandater: US National Institutes of Health
Tilgjengelige et eller annet sted: 83
Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study
R Nanda, LQM Chow, EC Dees, R Berger, S Gupta, R Geva, L Pusztai, ...
Journal of Clinical oncology 34 (21), 2460-2467, 2016
Mandater: US National Institutes of Health
Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively …
R Nanda, MC Liu, C Yau, R Shatsky, L Pusztai, A Wallace, AJ Chien, ...
JAMA oncology 6 (5), 676-684, 2020
Mandater: US National Institutes of Health
Adaptive randomization of veliparib–carboplatin treatment in breast cancer
HS Rugo, OI Olopade, A DeMichele, C Yau, LJ van’t Veer, MB Buxton, ...
New England Journal of Medicine 375 (1), 23-34, 2016
Mandater: US National Institutes of Health
Enzalutamide for the treatment of androgen receptor–expressing triple-negative breast cancer
TA Traina, K Miller, DA Yardley, J Eakle, LS Schwartzberg, ...
Journal of clinical oncology 36 (9), 884-890, 2018
Mandater: US National Institutes of Health
Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer
D Huo, F Ikpatt, A Khramtsov, JM Dangou, R Nanda, J Dignam, B Zhang, ...
Journal of clinical oncology 27 (27), 4515-4521, 2009
Mandater: US National Institutes of Health
TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes
NM Tung, ME Robson, S Ventz, CA Santa-Maria, R Nanda, PK Marcom, ...
Journal of Clinical Oncology 38 (36), 4274-4282, 2020
Mandater: Susan G. Komen
Adaptive randomization of neratinib in early breast cancer
JW Park, MC Liu, D Yee, C Yau, LJ van’t Veer, WF Symmans, M Paoloni, ...
New England Journal of Medicine 375 (1), 11-22, 2016
Mandater: US National Institutes of Health
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients
C Yau, M Osdoit, M van der Noordaa, S Shad, J Wei, D de Croze, ...
The Lancet Oncology 23 (1), 149-160, 2022
Mandater: US National Institutes of Health, Cancer Research UK, National Institute for …
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2 …
MF Rimawi, IA Mayer, A Forero, R Nanda, MP Goetz, AA Rodriguez, ...
Journal of clinical oncology 31 (14), 1726-1731, 2013
Mandater: US National Institutes of Health
Advances in breast cancer: pathways to personalized medicine
OI Olopade, TA Grushko, R Nanda, D Huo
Clinical Cancer Research 14 (24), 7988-7999, 2008
Mandater: US National Institutes of Health
The role of tumor-associated macrophages in breast cancer progression
E Obeid, R Nanda, YX Fu, OI Olopade
International journal of oncology 43 (1), 5-12, 2013
Mandater: US National Institutes of Health
The impact of site-specific digital histology signatures on deep learning model accuracy and bias
FM Howard, J Dolezal, S Kochanny, J Schulte, H Chen, L Heij, D Huo, ...
Nature communications 12 (1), 4423, 2021
Mandater: US National Institutes of Health
Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer: Translational Breast Cancer …
JF De Los Santos, A Cantor, KD Amos, A Forero, M Golshan, JK Horton, ...
Cancer 119 (10), 1776-1783, 2013
Mandater: US National Institutes of Health
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
L Pusztai, C Yau, DM Wolf, HS Han, L Du, AM Wallace, E String-Reasor, ...
Cancer cell 39 (7), 989-998. e5, 2021
Mandater: US National Institutes of Health
Informasjon om publisering og finansiering fastsettes automatisk av et datamaskinprogram